Development of a phospholipid nanoparticle and small molecule-based combination drug for the treatment of lethal sepsis

Active Grant Awarded

Award ID
R44GM165137
Recipient
Awarding agency
Obligated
$690,878

Award facts

Assistance listing
93.859 Biomedical Research and Research Training
Completion date 9% complete
Place of performance
Kansas City, MO 64108, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services, National Institutes of Health, National Institute of General Medical Sciences awarded Vivacelle Bio Inc. $690,878 in obligated funding on September 11, 2026, under Biomedical Research and Research Training (CFDA 93.859). The award is a grant under SBIR Phase II, with ultimate completion on August 31, 2028, and work performed in Kansas City, MO 64108.

The recipient will further develop and validate VBI-Optimum (VBI-O), a combination of a phospholipid nanoparticle colloid (PNC) and ethyl-3-hydroxybutyrate (EHB) for septic shock that modulates macrophage function and inflammatory signaling. Planned work includes optimizing PNC composition, identifying the EHB dose that provides additive or synergistic effect through increased survival in cecal ligation and laceration (CLL) rats, and evaluating cellular viability and inflammatory gene expression in peritoneal immune cells after treatment. The work also includes pharmacokinetic and histopathological assessments, an evaluation of the mechanism of action, and demonstration of safety and efficacy in rats and rabbits. As proposed, physicians would prescribe VBI-O, administered by injection into the abdominal cavity alongside antibiotics.

The source identifies no sub-recipients.

Description

Abstract
Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to an infection. An estimated 1.7 million adults are affected by sepsis, and 350,000 among them succumb to IT every year in the US alone. Currently, there are no FDA-approved drugs for treating sepsis since previous clinical trials proved unsuccessful. Conventional antibiotic treatment is still one of the mainstays in the management of sepsis, and a large number of resources are being pumped into the development of new antibiotics. However, the ever- increasing antibiotic resistance of bacteria poses serious concerns. Hence, there is a critical unmet need for a treatment of sepsis that does not rely on the use of antibiotics. To this end, vivacelle BIO INC (VBI) is developing VBI-optimum (VBI-O), an innovative combination of a phospholipid nanoparticle colloid (PNC) with ethyl-3- hydroxybutyrate (EHB), to treat septic shock by modulating macrophage function and inflammatory signaling. Physicians will be able to prescribe VBI-O, and the administration of the drug will be via a simple injection into the abdominal cavity along with antibiotics as opposed to intravenous antibiotics alone. In this sbir phase II, VBI will further develop and validate the optimum combination of PNC and EHB (VBI-O), evaluate its mechanism of action and demonstrate its safety and efficacy profile in rats and rabbits. To achieve these targets, we will first optimize composition of the PNC and identify the right EHB dose to combine with the PNC to provide additive and/or synergistic effect, in the form of increase in survival rates of cecal ligation and laceration (CLL) rats. Cellular viability and inflammatory gene expression in peritoneal immune cells following VBI-O treatment will then be evaluated, alongside pharmacokinetic and histopathological assessments. Toxicology studies in rats and rabbits will also be performed determine the minimum effective dose, maximum tolerated dose, and long- term safety in healthy animals. Successful completion of this phase II sbir project will enable studies with cgmp-grade reagents, laying the groundwork for an IND application and first-in-human trials to assess VBI-O's safety and efficacy in sepsis.

Quick answers

Who received award R44GM165137?

R44GM165137 was awarded to Vivacelle Bio Inc. by National Institute of General Medical Sciences (National Institutes of Health) on September 11, 2026.

How much is award R44GM165137 worth?

$690,878 has been obligated on R44GM165137.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award